Suggested remit: To appraise the clinical and cost effectiveness of selumetinib within its marketing authorisation for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over.
 
Status In progress
Process HST
ID number 1590

Provisional Schedule

Expected publication 05 May 2022

Project Team

Project lead Daniel Davies

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors AstraZeneca (selumetinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Childhood Tumour Trust
  Nerve Tumours UK
Professional groups British Paediatric Neurology Association
  Royal College of Physicians

Commentators

Associated public health groups None
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
02 December 2021 - 06 January 2022 Evaluation consultation: 1
10 November 2021 Committee meeting: 1
15 June 2021 In progress. In progress
15 June 2021 Invitation to participate
01 March 2021 Please note that following on from a request received from the company, the timelines for this evaluation have been revised and it is now anticipated to begin in mid-June 2021 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early August 2021. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
21 April 2020 Topic update: this evaluation has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
01 November 2019 (10:00) Scoping workshop (London)
19 September 2019 - 17 October 2019 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance